VX-770 for the Treatment of Chronic Bronchitis

NCT ID: NCT03251911

Last Updated: 2022-02-17

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-01
• Study Completion Date: 2022-02-01

Brief Summary

This research study will test how well a new drug affects bronchiectasis or chronic bronchitis. The new drug, Ivacaftor (KALYDECO), is a drug that has recently been approved by the U.S. Food and Drug Administration (FDA) for patients with a lung disease called Cystic Fibrosis (CF). It has not been approved for use in patients with bronchiectasis or chronic bronchitis.

Detailed Description

The study is an open label study of orally-administered ivacaftor in subjects with chronic bronchitis and/or bronchiectasis. Subjects will be administered the study drug ivacaftor 150 mg twice daily (BID). The study drug is commercially available and will be purchased by the participant.

Conditions

Chronic Bronchitis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ivacaftor (VX770)

Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction

Group Type: EXPERIMENTAL

Ivacaftor (VX-770)

Intervention Type: DRUG

of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction

Interventions

Ivacaftor (VX-770)

of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or Female age 18 years
• A Clinical diagnosis of Bronchiectasis and/or Chronic Bronchitis in the investigators opinion
• Exhibit symptoms of chronic bronchitis as defined by the Medical Research Council
• FEV1 percent predicted greater than 40 percent Post Bronchodilator
• Clinically stable in the last 4 weeks with no evidence of exacerbation
• Weight of 40 kg to120 kg
• Willingness to use at least one form of acceptable birth control including abstinence, condom with spermicide, or hormonal contraceptives
• Willing to monitor blood glucose if known history of diabetes mellitus requiring insulin or medical therapy
• Element of CFTR Dysfunction, as defined by Sweat Chloride

Exclusion

• Daytime use of Oxygen Therapy
• Documented history of drug abuse within the last year
• Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary disease within 28 days before receiving the first dose of study drug.
• Cirrhosis or elevated liver transaminases > 3X ULN
• GFR < 50 estimated by Cockroft-Gault
• Any illness or abnormal lab finding that, in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject.
• Pregnant or Breastfeeding
• Subjects taking any inhibitors or inducers of CYP3A4, including certain herbal medications and grapefruit juice. (Excluded medications and foods including the drugs and foods are provided in the appendix document)
• Uncontrolled Diabetes
• Clinically significant arrhythmias or conduction abnormalities that in the opinion of the investigator that affect patient safety

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

George Solomon

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Countries

United States

Other Identifiers

F160914011

Identifier Type: -

Identifier Source: org_study_id